

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4160988

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GHASSAN S. KASSAB	02/04/2016
JOSE A. NAVIA SR.	02/04/2016
RECEIVING PARTY DATA	
Name:	CVDEVICES, LLC
Street Address:	11107 ROSELLE STREET
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15363377
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3179666835
Email:	mark@rsindy.com
Correspondent Name:	MARK C. REICHEL, REICHEL STOHR LLP
Address Line 1:	212 WEST 10TH STREET
Address Line 2:	SUITE A-285
Address Line 4:	INDIANAPOLIS, INDIANA 46202
ATTORNEY DOCKET NUMBER:	R-P01757-US-09 A2
NAME OF SUBMITTER:	MARK C. REICHEL
SIGNATURE:	/Mark C. Reichel/
DATE SIGNED:	11/29/2016
Total Attachments: 4	
source=RP01757US09Assignment2#page1.tif	
source=RP01757US09Assignment2#page2.tif	
source=RP01757US09Assignment2#page3.tif	
source=RP01757US09Assignment2#page4.tif	

PATENT ASSIGNMENT

This PATENT ASSIGNMENT (the "Assignment") is entered into as of this 4th day of February, 2016 (the "Effective Date") by and among Ghassan S. Kassab, an individual having a principal address at 2505 Hidden Valley Place, La Jolla, CA 92037 ("GSK"), Jose A. Navia, Sr., an individual having a principal address at Suipacha 1308, Apt. 4B, Buenos Aires, 1011, Argentina ("JAN"), and CVDevices, LLC, a limited liability company having a principal address at 11107 Roselle Street, San Diego, CA 92121 ("CVD"). GSK, JAN, and CVD may be individually referred to herein as a "Party" or collectively referred to herein as the "Parties."

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1. Assignment of Patents and/or Patent Applications. GSK and JAN (collectively the "Assignors") each hereby irrevocably assign, transfer, and convey to CVD all of their respective right, title, and interest in, to, and under the inventions and patent applications and/or patents set forth in EXHIBIT A attached hereto and hereby incorporated by reference herein, including, without limitation, (i) all inventions and improvements disclosed therein, (ii) all letters patent or similar legal protection granted therefor in the United States, its territorial possessions, and in all foreign countries, unions, or regions, (iii) all continuations, divisions, continuations-in-part, substitutions, reissues, renewals, substitutes, and extensions thereof and applications therefor, in the United States and its territorial possessions and in all foreign countries, unions, or regions, (iv) any and all patents and patent applications that claim priority to any of the foregoing, and (v) all rights to enforce including, but not limited to, the right to sue and collect damages for any past or future infringements throughout the world (the "Assigned Patents").

2. Filing and Recording Instruments of Transfer. CVD, at its sole discretion, shall make all filings with the requisite intellectual property offices in order to confirm, effectuate, or record this Assignment of the Assigned Patents to CVD granted herein. CVD shall be responsible to file and record any and all documents of conveyance as may be necessary to vest in CVD, as a matter of public record, all of the Assigned Patents.

3. Appointment. The Assignors hereby constitute and appoint CVD, and its successors and assigns, the true and lawful attorney or attorneys in fact of the Assignors, with the full power of substitution, for it and in its name and stead or otherwise, to institute and prosecute from time to time, any proceedings at law, in equity, or otherwise, that CVD, or its successors or assigns, may reasonably deem proper in order to assert or enforce any claim, right, or title of any kind in and to the Assigned Patents, and to defend and compromise any and all actions, suits, or proceedings, in respect to any of the foregoing, and generally to do any and all such acts and things in relation thereto as CVD, or its successors or assigns, shall reasonably deem advisable, including, but not limited to, the execution and delivery of any and all assignments and instruments in furtherance hereof. The Assignors declare that the appointment hereby made and the powers hereby granted are coupled with an interest and shall be irrevocable by the Assignors.

4. Miscellaneous. This Assignment shall be governed, construed, and enforced in accordance with the laws of the State of Indiana, without regard to any state's choice of laws to

the contrary. This Assignment shall inure to the benefit of, and be binding upon, the Parties hereto and their respective successors and assigns. This Assignment may be executed in multiple counterparts, each of which shall be deemed an original and together shall constitute one in the same instrument. Facsimile copies of any signature to this Assignment shall be deemed an original signature hereto.

IN WITNESS WHEREOF, the Parties have executed this Assignment as of the Effective Date.

"GSK"

GHASSAN S. KASSAB



"JAN"

JOSE A. NAVIA, SR.



"CVD"

CVDEVICES, LLC



Ghassan S. Kassab
Manager

the contrary. This Assignment shall inure to the benefit of, and be binding upon, the Parties hereto and their respective successors and assigns. This Assignment may be executed in multiple counterparts, each of which shall be deemed an original and together shall constitute one in the same instrument. Facsimile copies of any signature to this Assignment shall be deemed an original signature hereto.


IN WITNESS WHEREOF, the Parties have executed this Assignment as of the Effective Date.

"GSK"

GHASSAN S. KASSAB

"JAN"

JOSE A. NAVIA, SR.



"CVD"

CVDEVICES, LLC

Ghassan S. Kassab
Manager

EXHIBIT A

US Serial No.	Patent No. (if Issued)	Filing or US § 371 Date	Internal Ref. No.
61/682,345		August 13, 2012	P01593-US-03
13/965,548		August 13, 2013	P01593-US-04
61/682,348		August 13, 2012	P01757-US-05
13/965,533		August 13, 2013	P01757-US-07
61/682,351		August 13, 2012	P01778-US-03
13/965,565		August 13, 2013	P01778-US-05